Gommers Jip S M, Diederen Milou, Wilkinson Chris, Turnbull Deborah, Mol Ben W J
Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 60, 6229 ER, Maastricht, The Netherlands.
Faculty of Health, Medicine and Life Sciences, Maastricht University, Universiteitssingel 60, 6229 ER, Maastricht, The Netherlands.
Eur J Obstet Gynecol Reprod Biol. 2017 Nov;218:73-84. doi: 10.1016/j.ejogrb.2017.09.014. Epub 2017 Sep 18.
Induction of labour is one of the most frequently applied obstetrical interventions globally. Many studies have compared the use of balloon catheters with pharmacological agents. Although the safety of the balloon catheter is often mentioned, little has been written about the total spectrum of maternal and fetal morbidity associated with induction of labour using a balloon catheter. We evaluated the safety of labour induction with a transcervical balloon catheter by conducting a literature review with pooled risk assessments of the maternal, fetal and neonatal morbidity. We searched Medline, EMBASE and CINAHL as well as the Cochrane database using the Keywords 'induction of labour', 'cervical ripening', 'transcervical balloon', 'balloon catheter' and 'Foley balloon'. We did not use language or date restrictions. Randomized and quasi-randomized controlled trials as well as observational studies that contained original data on occurrence of maternal, fetal or neonatal morbidity during induction of labour with the balloon catheter were included. Studies were excluded if the balloon catheter was used concurrently with oxytocin and concurrently or consecutively with misoprostol, dinoprostone or extra-amniotic saline infusion. Study selection and quality assessment was performed by two authors independently using a standardized critical appraisal instrument. Outcomes were reported as weighted mean rates. We detected 84 articles reporting on 13,791 women. The overall risk of developing intrapartum maternal infection was 11.3% (912 of 8079 women), 3.3% (151 of 4538 women) for postpartum maternal infection and 4.6% (203 of 4460 women) for neonatal infection. Uterine hypercontractility occurred in 2.7% (148 of 5439) of the women. Uterine rupture after previous caesarean section occurred in 1.9% of women (26 of 1373), while other major maternal complications had an occurrence rate of <1%. The risk for developing minor maternal complications was <2%. The risk of developing a non-reassuring fetal heart rate was 10.8% (793 of 7336 women), 10.1% (507 of 5008 women) for fetal distress and 14.0% (460 of 3295 women) for meconium stained liquor. Neonatal death occurred in 0.29% (6 of 2058) of the deliveries and NICU admission in 7.2% (650 of 9065 deliveries). This review shows that labour induction with a balloon catheter is a safe intervention, with intrapartum maternal infection being the only reasonable risk above 10%.
引产是全球最常用的产科干预措施之一。许多研究比较了球囊导管与药物制剂的使用情况。尽管经常提到球囊导管的安全性,但关于使用球囊导管引产相关的母婴发病率的整体情况却鲜有著述。我们通过对母婴及新生儿发病率的汇总风险评估进行文献综述,评估经宫颈球囊导管引产的安全性。我们使用关键词“引产”“宫颈成熟”“经宫颈球囊”“球囊导管”和“福勒球囊”在医学文献数据库(Medline)、荷兰医学文摘数据库(EMBASE)、护理学与健康领域数据库(CINAHL)以及考克兰数据库中进行检索。我们未设置语言或日期限制。纳入了随机和半随机对照试验以及观察性研究,这些研究包含了使用球囊导管引产期间母婴及新生儿发病率的原始数据。如果球囊导管与缩宫素同时使用,或与米索前列醇、地诺前列酮或羊膜外生理盐水输注同时或相继使用,则排除相关研究。由两位作者独立使用标准化的批判性评价工具进行研究选择和质量评估。结果以加权平均率报告。我们检索到84篇报道13791名女性情况的文章。产时母体感染的总体风险为11.3%(8079名女性中的912例),产后母体感染为3.3%(4538名女性中的151例),新生儿感染为4.6%(4460名女性中的203例)。2.7%(5439名中的148例)的女性出现子宫过度收缩。既往剖宫产术后子宫破裂发生在1.9%的女性中(1373名中的26例),而其他主要母体并发症的发生率<1%。发生轻微母体并发症的风险<2%。出现胎心异常的风险为10.8%(7336名女性中的793例),胎儿窘迫为10.1%(5008名女性中的507例),羊水粪染为14.0%(3295名女性中的460例)。新生儿死亡发生在0.29%(2058例分娩中的6例)的分娩中,新生儿重症监护病房(NICU)收治率为7.2%(9065例分娩中的650例)。本综述表明,使用球囊导管引产是一种安全的干预措施,产时母体感染是唯一超过10%的合理风险。